About Fitzgerald
Fitzgerald is a Healthcare company based in Acton (United States) founded in 1989, and was acquired by Biosynth in April 2023. Biological reagents are manufactured and marketed for research and diagnostics. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Proteomics. Its competitors include GenScript, Epitomics and Vector Laboratories; 2 of its 3 listed competitors have raised funding.
Company details
Fitzgerald manufactures and markets a wide variety of biological reagents to research and diagnostic customers. Its product line includes primary antibodies, secondary antibodies, recombinant proteins, Conjugated proteins, Hapten conjugates, Complements, Blocking peptidesNative Proteins ELISA kits, Serum and Plasma, and other biological reagents such as Enzymes, Poly-HRP products, Colloidal gold Silver products, Chemical reference, Diluents, Surfactants, Substrates, IHC reagents, Mounting media preservatives, Controls calibrators and Isotype controls .
- Headquarters Acton, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website fitzgerald-fii.com
- Social LinkedIn X Facebook
- Acquired by Biosynth (Apr 2023)
Investors in Fitzgerald
Fitzgerald has secured backing from 1 investor. Prominent investors backing the company include Biosynth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biosynth is engaged in supplying critical raw materials and services for life sciences and diagnostics. | 1966 | biosynth.com | Thal, Switzerland |
Investor details for Fitzgerald
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Fitzgerald
2 dated milestones of Fitzgerald across 34 years, from founding to its latest funding, stage changes and deals.
- Founded Fitzgerald is founded.
- Exit Acquired by Biosynth.
Competitors of Fitzgerald
Fitzgerald has 3 listed competitors in our database, 2 of them funded. They include GenScript, Epitomics and Vector Laboratories.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| epitomics.com | 2001 | Burlingame, United States | $16.21M | Monoclonal antibody technology and products are developed by Epitomics. | ||
| vectorlabs.com | 1976 | Burlingame, United States | Labeling and detection reagents immunohistochemistry studies and other life science research applications |
Detailed competitors of Fitzgerald
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Fitzgerald
Websites that share an audience with Fitzgerald (fitzgerald-fii.com).
Websites whose visitors overlap most with Fitzgerald. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| abcam.com | 100% | 602.8K | #91,958 | View details | |
| scbt.com | 92% | 444.3K | #138,937 | View details | |
stratech.co.uk | stratech.co.uk | 87% | #1,782,305 | – | |
| rndsystems.com | 84% | 349K | #159,292 | View details | |
| peprotech.com | 84% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for Fitzgerald
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Fitzgerald (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Fitzgerald
Fitzgerald was founded in 1989.
Fitzgerald is headquartered in Acton, United States.
Fitzgerald manufactures and markets a wide variety of biological reagents to research and diagnostic customers. Its product line includes primary antibodies, secondary antibodies, recombinant proteins, Conjugated proteins, Hapten conjugates, Complements, Blocking peptidesNative Proteins ELISA kits, Serum and Plasma, and other biological reagents such as Enzymes, Poly-HRP products, Colloidal gold Silver products, Chemical reference, Diluents, Surfactants, Substrates, IHC reagents, Mounting media preservatives, Controls calibrators and Isotype controls .
Fitzgerald's top competitors include GenScript, Epitomics and Vector Laboratories.
Fitzgerald has 1 investor. Key investors include Biosynth.
Yes. Fitzgerald was acquired by Biosynth in April 2023.